Patents by Inventor Sandip Mehta

Sandip Mehta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250144013
    Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.
    Type: Application
    Filed: January 10, 2025
    Publication date: May 8, 2025
    Inventors: Sandip MEHTA, Manish Kumar UMRETHIA, Jayanta MANDAL
  • Patent number: 12226526
    Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.
    Type: Grant
    Filed: August 8, 2024
    Date of Patent: February 18, 2025
    Assignee: LIQMEDS WORLDWIDE LIMITED
    Inventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
  • Patent number: 12194143
    Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water, a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.
    Type: Grant
    Filed: August 8, 2024
    Date of Patent: January 14, 2025
    Assignee: LIQMEDS WORLDWIDE LIMITED
    Inventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
  • Publication number: 20240398700
    Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water, a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.
    Type: Application
    Filed: August 8, 2024
    Publication date: December 5, 2024
    Inventors: Sandip MEHTA, Manish Kumar UMRETHIA, Jayanta MANDAL
  • Publication number: 20240390268
    Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.
    Type: Application
    Filed: August 8, 2024
    Publication date: November 28, 2024
    Inventors: Sandip MEHTA, Manish Kumar UMRETHIA, Jayanta MANDAL
  • Publication number: 20240374516
    Abstract: A ready to use oral pharmaceutical suspension that includes dasatinib or a pharmaceutically acceptable salt thereof, a suspending agent, a wetting agent, a binder or filler, a buffering agent in an amount sufficient to provide a pH of from about 4 to about 8 and water.
    Type: Application
    Filed: July 23, 2024
    Publication date: November 14, 2024
    Applicant: ONCOSOL LIMITED
    Inventors: SANDIP MEHTA, MANISHKUMAR UMRETHIA, JAYANTA MANDAL
  • Publication number: 20240366588
    Abstract: This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin.
    Type: Application
    Filed: May 10, 2024
    Publication date: November 7, 2024
    Applicants: FTF PHARMA PRIVATE LIMITED, LM MANUFACTURING LIMITED
    Inventors: Sandip MEHTA, Manish Kumar UMRETHIA, Jayanta MANDAL
  • Patent number: 12097284
    Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.
    Type: Grant
    Filed: February 15, 2024
    Date of Patent: September 24, 2024
    Assignee: LIQMEDS WORLDWIDE LIMITED
    Inventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
  • Patent number: 12097285
    Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.
    Type: Grant
    Filed: February 15, 2024
    Date of Patent: September 24, 2024
    Assignee: LIQMEDS WORLDWIDE LIMITED
    Inventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
  • Patent number: 12083222
    Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an anti-cancer active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the anti-cancer active pharmaceutical ingredient is selected from ibrutinib, nilotinib, dasatinib, sunitinib, sorafenib, erlotinib, and capecitabine.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: September 10, 2024
    Assignee: ONCOSOL LIMITED
    Inventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
  • Publication number: 20240293393
    Abstract: This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin.
    Type: Application
    Filed: May 2, 2024
    Publication date: September 5, 2024
    Inventors: Sandip MEHTA, Manish Kumar UMRETHIA, Jayanta MANDAL
  • Publication number: 20240216373
    Abstract: Imatinib is approved and marketed in solid oral dosage forms which may be dispersed in water or apple juice for patients having swallowing difficulty. Dispersion of Imatinib solid dosage forms in apple juice may increase palatability and patient compliance but apple juice may not be available all the time for administration. Further, dispersion of Imatinib solid oral dosage forms may not administer correct and consistent dose of medicine every time. The present invention therefore provides liquid dosage forms of Imatinib which correctly and consistently administers correct dose of drug to the patients.
    Type: Application
    Filed: January 16, 2024
    Publication date: July 4, 2024
    Inventors: Sandip MEHTA, Vijay PATEL, Manish UMRETHIA, Jayanta Kumar MANDAL
  • Publication number: 20240207175
    Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.
    Type: Application
    Filed: February 15, 2024
    Publication date: June 27, 2024
    Inventors: Sandip MEHTA, Manish Kumar UMRETHIA, Jayanta MANDAL
  • Patent number: 12016857
    Abstract: This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin.
    Type: Grant
    Filed: May 2, 2023
    Date of Patent: June 25, 2024
    Assignees: FTF PHARMA PRIVATE LIMITED, LM MANUFACTURING LTD.
    Inventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
  • Publication number: 20240197625
    Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.
    Type: Application
    Filed: February 15, 2024
    Publication date: June 20, 2024
    Inventors: Sandip MEHTA, Manish Kumar UMRETHIA, Jayanta MANDAL
  • Publication number: 20240165024
    Abstract: Disclosed herein is a pharmaceutical oral suspension, comprising: mycophenolate mofetil in an amount of about 200 mg/mL; one or more cosolvents comprising ethanol, a polyethylene glycol, a sorbitol, glycerin, propylene glycol, benzyl alcohol, or a combination thereof in an amount of from about 5% w/w to about 30% w/w; one or more pharmaceutically acceptable excipients selected from a suspending agent, a preservative, a sweetener, an antifoaming agent, a wetting agent, a buffering agent, and a flavoring agent; and a vehicle comprising water. The pharmaceutical oral suspension has improved stability, palatability with high dose of active ingredient.
    Type: Application
    Filed: January 25, 2024
    Publication date: May 23, 2024
    Inventors: Sandip MEHTA, Manish UMRETHIA, Henil PATEL, Jayanta Kumar MANDAL
  • Patent number: 11957681
    Abstract: Imatinib is approved and marketed in solid oral dosage forms which may be dispersed in water or apple juice for patients having swallowing difficulty. Dispersion of Imatinib solid dosage forms in apple juice may increase palatability and patient compliance but apple juice may not be available all the time for administration. Further, dispersion of Imatinib solid oral dosage forms may not administer correct and consistent dose of medicine every time. The present invention therefore provides liquid dosage forms of Imatinib which correctly and consistently administers correct dose of drug to the patients.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: April 16, 2024
    Assignee: SHORLA PHARMA LIMITED
    Inventors: Sandip Mehta, Vijay Patel, Manish Umrethia, Jayanta Kumar Mandal
  • Patent number: 11931455
    Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.
    Type: Grant
    Filed: July 31, 2023
    Date of Patent: March 19, 2024
    Assignee: LIQMEDS WORLDWIDE LIMITED
    Inventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
  • Patent number: 11918684
    Abstract: The present invention provides pharmaceutical composition of immunosuppressive agent in oral suspension dosage form. The oral suspension composition comprises of immunosuppressive agent with other pharmaceutical excipients such as vehicle, suspending agent, solvent or cosolvent, preservative, sweetener, antifoaming agent, wetting agent, buffering agent and flavouring agent. The present invention oral suspension having improved stability, palatability with high dose of active ingredient. The present invention provides oral suspension with flavor that has masked bitter taste of the drug and eliminates difficulty of administration. Further, the present invention also provides a convenient, easy process for preparation thereof.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: March 5, 2024
    Assignee: LIQMEDS WORLDWIDE LIMITED
    Inventors: Sandip Mehta, Manish Umrethia, Henil Patel, Jayanta Kumar Mandal
  • Publication number: 20230372238
    Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.
    Type: Application
    Filed: July 31, 2023
    Publication date: November 23, 2023
    Inventors: Sandip MEHTA, Manish Kumar UMRETHIA, Jayanta MANDAL